

## Systematic Review

# Evaluation Of Various Progesterone Therapy Routes For Luteal Phase Support In IVF: A Systematic Review And Meta-Analysis

Majid Vatankhah<sup>1</sup>, Arman Hakemi<sup>2</sup>, Fatemeh Rahmanian<sup>3</sup>, Somayeh Hoseini<sup>4</sup>, Samaneh Abiri<sup>3</sup>, Farideh Mogharab<sup>5</sup>, Lohrasb Taheri<sup>6</sup>, Rezvan Heidari<sup>7</sup>, Marzieh Haghbeen<sup>8\*</sup>

1. Department of Anesthesiology, Critical Care and Pain Management Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
2. Department of Emergency Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
3. Department of Emergency Medicine, Jahrom University of Medical Sciences, Jahrom, Iran.
4. MSC in Midwifery Counseling, Jahrom University of Medical Sciences, Jahrom, Iran.
- 5., Department of Obstetrics and Gynecology, Jahrom University of Medical Sciences, Jahrom, Iran.
6. Department of Surgery, Jahrom University of Medical Sciences, Jahrom, Iran.
7. Vice Chancellor for Health, Shiraz University of Medical Sciences, Shiraz, Iran.
8. Women's Health and Disease Research Center, Jahrom University of Medical Sciences, Jahrom, Iran.

**\*Corresponding Author: Marzieh Haghbeen**, Women's Health and Disease Research Center, Jahrom University of Medical Sciences, Jahrom, Iran. E-mail: [drhaghbeenoncosurg@gmail.com](mailto:drhaghbeenoncosurg@gmail.com). ORCID: <https://orcid.org/0000-0003-3972-747X>.

## Abstract:

### Background:

The progesterone secreted from the ovary until the seventh week of pregnancy is required to maintain pregnancy. In fertility-assisted cycles, administration of GnRH agonists can cause Corpus luteum failure, and progesterone secreted from the ovary will not be sufficient to protect pregnancy. The best way to prevent this situation is to support progesterone administration.

Objective: This study aimed to rank the best route of progesterone administration in luteal phase support.

### Methods:

Randomized controlled trials (RCTs) of progesterone for the luteal phase support were identified from online databases of Scopus, Google Scholar, Pubmed. Treatment efficacy was defined as ongoing pregnancy. Data were extracted and analyzed using odds ratios (ORs). A Bayesian network meta-analysis was performed using the Markov chain Monte Carlo method in WinBUGS and NetMetaXL.

### Results:

Total 1176 participants were studied in 16 trials of 6 separate progesterone routes including vaginal progesterone gel, progesterone sub q, Dydrogesterone, Cap 200 mg TID, Cap 200 mg BID, and progesterone IM. Comparison test shows better likelihood of SUCRA followed by vaginal progesterone gel (77.8%), progesterone sub q (55.49%), Dydrogesterone (53.97%), Cap 200 mg TID (50.67%), Cap 200 mg BID (48.99%) and finally progesterone IM (13.06%).

### Conclusion:

This study ranked as the best route of progesterone therapy for luteal phase support, through the reviewed studies.

**Keywords:** Network meta-analysis, Progesterone, Luteal Phase Support, IVF.

Submitted: 10 March 2021, Revised: 20 April 2021, Accepted: 27 April 2021

## Introduction

In vitro fertilization (IVF) is a set of complex processes that comes with the help of fertility and help infertile people to perform the fertilization process properly (1–3). During IVF, the mature ovum is taken from the ovaries and fertilized by sperm in the laboratory. The fertilized ovum (embryo) or a set of ovum transferred to the uterus. A full cycle of IVF takes about three weeks. Sometimes these steps can be divided into several stages, and this process may take longer to complete(1,4,5). IVF is the most effective reproductive technology. The success of IVF treatment depends on many factors such as age and the causes of infertility. In addition, IVF can be time consuming, expensive and sometimes dangerous. If more than one embryo transfers into the uterus, IVF may lead to multiple pregnancies (2,4). The menstrual cycle is created to maintain fertility

in women under the control of the endocrine system. This cycle is divided into three phases: Follicular phase, ovulation phase and luteal phase (6,7). The luteal phase in every woman's body begins at the end of ovulation time and ends the day before the next ovulation period. The luteal phase in the woman's body usually takes about 14 days. In this phase, the corpus luteum that is a structure grows on the surface of the ovaries, which release the mature ovum at the time of ovulation. The Corpus luteum, which produces the progesterone hormone in the woman's body(3,5,6). The progesterone hormone secreted from the corpus luteum makes the uterine wall suitable for the ovum Implantation process. This supportive effect of progesterone on the uterine wall is called luteal phase support. Luteal phase support is essential for IVF process success (1,3,6).

**Table 1. Pregnancy rate in studies**

	Vaginal gel	Cap 200 mg Tid	Pes 200 mg Bid	Dydrogesterone	IM	sub-Q
<b>Geber (8)</b>	44.26	36.07				
<b>Simunic (9)</b>	30.71	28.97				
<b>Kleinstei (10)</b>	22.17	25.23				
<b>Tay (11)</b>	36.11	34.55	34.29			
<b>Ng (12)</b>	34.29		30			
<b>Ludwig (13)</b>	28.77	18.87				
<b>Tomic (14)</b>	30.29			27.95		
<b>Chi-hong ho (15)</b>	56.72				33.77	
<b>Lockwood (16)</b>	29.07					27.43
<b>Baker (17)</b>	43.25					40.75
<b>Zaman (18)</b>	32.16				28.02	
<b>Doblinger (19)</b>	38.56					35.85
<b>Yanushpolsky (20)</b>	47.62				19.09	
<b>Yanushpolsky (21)</b>	45.15				42.29	
<b>Chi (22)</b>	40.19				34.13	
<b>Berjis (23z)</b>	15.58				18.82	

Sub-Q: Subcutaneous; IM: Intramuscular.

Creating and strengthening luteal phase support is crucial to increase the success chance of the IVF process. Different forms of artificial progesterone types are used for this purpose. In this review and Network meta-analysis study, we aimed to compare the efficacy of different progesterone types used in luteal phase support in IVF.

**Methods**

Published randomized controlled trials (RCTs) are the eligible type of studies for inclusion. We do not include studies of inadequate randomization and studies with a lack of needed indexes. Studies with participation of infertile women trying to conceive by IVF method, and using any dose or route of progesterone administration as Intervention for Luteal phase support were included. Medication had to be administered after the day of ovulation.

**Measured outcome**

Ongoing pregnancy, as our main outcome, was defined as evidence of a 12-week fetal heart movement with gestational sac, confirmed by ultrasonography.

**Search strategy**

We searched for all published and RCTs evaluating luteal phase support in IVF/ICSI patients from 1990 to 2020. We developed the search strategy in consultation with the Cochrane Gynecology and Fertility (CGF) Group Information Specialists and then we searched in Google Scholar, PubMed, Science direct, etc. for eligible studies for analyses. In this study, IVF, luteal phase support progesterone and RCT were used as search keywords. We extracted data from included studies using a data extraction checklist designed and pilot-tested by our authors. We also extracted data on study characteristics as well as outcome data. When studies had multiple publications, we used the main trial report as the reference and then we derived additional details from secondary papers.

**Statistical methods**

WinBUGS program was used to perform a meta-analysis of the Bayesian network. Because the data sets given were dichotomous outcomes and included multi-arm trials, the study was focused on a binomial probability model which accounts for the use of multi-arm trials (7).

**Table 2. Efficiency of various routs of progesterone therapy expressed by OR**

<b>Vaginal progesterone gel</b>					
1.11 (0.77 – 1.59)	<b>subcutaneous progesterone</b>				
1.12 (0.57 – 2.16)	1.01 (0.47 – 2.13)	<b>Dydrogesterone</b>			
1.15 (0.78 – 1.63)	1.03 (0.62 – 1.71)	1.02 (0.49 – 2.26)	<b>Cap 200 mg TID</b>		
1.18 (0.50 – 2.59)	1.06 (0.42 – 2.61)	1.04 (0.37 – 3.03)	1.02 (0.44 – 2.36)	<b>Pes 200 mg BID</b>	
1.49 (1.12 – 2.08)	1.34 (0.84 – 2.25)	1.34 (0.66 – 2.86)	1.29 (0.83 – 2.17)	1.27 (0.56 – 3.30)	<b>progesterone IM</b>

Trials with zero cells in both arms and nodes with no occurrences have been excluded from

the evidence networks as they do not convey information or need comprehensible details

Meta-analyses were done for both fixed and random network effects, though the paradigm of fixed effects was used as the reference analysis. Using the methodology of Markov Chain Monte Carlo, we predicted point figures and 95 percent reliable odds ratio (OR) intervals. In the consistency model, NetMetaXL often plots the posterior mean deviance of the single data points in the inconsistency model against their posterior mean deviance to find certain gaps in the interventions network where there is inconsistency.

### Results

Finally, 1176 participants were studied in 16 trials of 6 separate progesterone routes including vaginal progesterone gel, subcutaneous progesterone, Dydrogesterone, Cap 200 mg TID, Pes 200 mg BID, and progesterone IM. The pregnancy rate in each study is shown for each arm in table 1.

The efficiency of various routes of progesterone therapy expressed by OR is shown in table 2. The relative effectiveness is plotted as an OR with a credible interval of 95 percent. Based on these findings, we determined the surface under the cumulative ranking curve (SUCRA), which is the optimal transformed value according to the ranking of each therapy. Comparison test shows better likelihood of SUCRA followed by vaginal progesterone gel (77.8%), progesterone sub q (55.49%), Dydrogesterone (53.97%), Cap 200 mg TID (50.67%), Cap 200 mg BID (48.99%) and finally progesterone IM (13.06%). Table 3 displays every treatment scheme's SUCRA. A higher SUCRA score suggests better treatment outcomes based on the indirect form of contrast. Heterogeneity (OR: 21.8 percent, 95 percent CI: 2.3 – 56.9) was not significant and no inconsistency was seen as shown in figure 1.

### Discussion


Progesterone is available in many different forms, including vaginal micronized gel,

vaginal suppository, oral tablets and injectable progesterone are widely used in the world. Intra-muscular progesterone is an oily compound that needs daily injections, whereas progesterone suppositories can be used in the rectum or vaginal direction to support the luteal phase. Muscle administration increases the serum progesterone level, but vaginal administration of the progesterone causes up to a 3-fold greater level of the drug than that obtained with intramuscular administration in the endometrial tissue. Dihydrogestron (Dofastone) is used in people with luteal phase deficiency and treatment for recurrent miscarriages. Its molecular structure and pharmacology resemble endogenous progesterone, although its oral dosage forms the same activity as endogenous progesterone. Many clinical trials have been published on the comparison of different routes of progesterone therapy in luteal phase support and subsequently, many meta-analysis studies have investigated these massive data. Part of the studies has focused on progesterone therapy along with human chorionic gonadotropin (hCG) or each of those alone (24).

**Table 3. SUCRA score of**

Treatment	SUCRA
Vaginal progesterone gel	0.7782
Subcutaneous progesterone	0.5549
Dydrogesterone	0.5397
Cap 200 mg TID	0.5067
Cap 200 mg BID	0.4899
IM progesterone	0.1306

Our study with a network meta-analysis methodology revealed that Vaginal progesterone gel had the best ranked between



**Figure 1. Consistency model of study**

other routes in evaluated studies while IM form had the least response to treatment; While a meta-analysis study by Pritts et al. revealed that IM progesterone is preferred to oral or vaginal route (25).

Injection form requires daily injections and may cause inflammatory reactions and rarely sterile abscesses, but its price is much cheaper than vaginal capsule formulation. In the vaginal method, it is easy to use and allergic reactions are rare but unfortunately, the cost is high (26).

In another meta-analysis conducted by Watters et al., short versus extended progesterones were compared and prolonged progesterone therapy was not considered to be necessary; while we did not assess progesterone cessation time in our study, which might be a confounding factor (27).

Another study, reviewing two studies, reported better efficiency of IVF outcomes in patients receiving oral dydrogesterone versus patients micronized vaginal progesterone (28); while in our study, better efficiency of vaginal progesterone was seen. our study revealed vaginal progesterone is superior to other routes; while Salehpour et al. (29) found no differences.

### Conclusion

This study ranked as the best route of progesterone therapy for luteal phase support, through the reviewed studies; while there were

lots of confounding factors and limitations due to the various dosing used in different studies.

### Acknowledgment

We would like to thank the Clinical Research Development Unit of Peymanieh Educational and Research and Therapeutic Center of Jahrom University of Medical Sciences for providing facilities for this work.

### References:

1. GRIESINGER, Georg, et al. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial. *Human Reproduction*, 2018, 33.12: 2212-2221..
2. FERRARETTI, Anna Pia, et al. No need for luteal phase support in IVF cycles after mild stimulation: proof-of-concept study. *Reproductive biomedicine online*, 2017, 34.2: 162-165..
3. WATTERS, Marianne, et al. Short Versus Extended Progesterone Supplementation for Luteal Phase Support in fresh IVF cycles: a systematic review and meta-analysis. *Reproductive BioMedicine Online*, 2019..
4. THOMSEN, Lise Haaber, et al. Reply: Low as well as high serum P4 levels in the early and mid-luteal phase reduce the chance of a live birth following IVF treatment with fresh embryo transfer. *Human Reproduction*, 2018..
5. MENDOZA-TESARIK, Raquel, et al. GnRH agonist treatment of luteal phase deficiency in HCG-triggered IVF cycles: a matched case-control study. *Reproductive biomedicine online*, 2019, 39.2: 225-230..
6. WEEDIN, Elizabeth, et al. Luteal-phase progesterone supplementation in non-IVF treatment: a survey of physicians providing infertility treatment. *Human Fertility*, 2019, 1-7.

7. Brown S, Hutton B, Clifford T, Coyle D, Grima D, Wells G, Cameron C. A Microsoft-Excel-based tool for running and critically appraising network meta-analyses—an overview and application of NetMetaXL. *Systematic reviews*. 2014 Dec;3(1):1-1.
8. Geber S, Moreira AC, de Paula SO, Sampaio M. Comparison between two forms of vaginally administered progesterone for luteal phase support in assisted reproduction cycles. *Reproductive biomedicine online*. 2007 Jan 1;14(2):155-8.
9. Simunic V, Tomic V, Tomic J, Nizic D. Comparative study of the efficacy and tolerability of two vaginal progesterone formulations, Crinone 8% gel and Utrogestan capsules, used for luteal support. *Fertility and sterility*. 2007 Jan 1;87(1):83-7.
10. Kleinstein J, Luteal Phase Study Group. Efficacy and tolerability of vaginal progesterone capsules (Utrogest™ 200) compared with progesterone gel (Crinone™ 8%) for luteal phase support during assisted reproduction. *Fertility and sterility*. 2005 Jun 1;83(6):1641-9.
11. Tay PY, Lenton EA. The impact of luteal supplement on pregnancy outcome following stimulated IVF cycles. *Medical Journal of Malaysia*. 2005 Jun 1;60(2):151.
12. Ng EH, Chan CC, Tang OS, Ho PC. A randomized comparison of side effects and patient convenience between Cyclogest® suppositories and Endometrin® tablets used for luteal phase support in IVF treatment. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2007 Apr 1;131(2):182-8.
13. Ludwig M, Schwartz P, Babahan B, Katalinic A, Weiss JM, Felberbaum R, Al-Hasani S, Diedrich K. Luteal phase support using either Crinone® 8% or Utrogest®: results of a prospective, randomized study. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2002 Jun 10;103(1):48-52.
14. Tomic V, Tomic J, Klaic DZ, Kasum M, Kuna K. Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2015 Mar 1;186:49-53.
15. Ho CH, Chen SU, Peng FS, Chang CY, Yang YS. Luteal support for IVF/ICSI cycles with Crinone 8%(90 mg) twice daily results in higher pregnancy rates than with intramuscular progesterone. *Journal of the Chinese Medical Association*. 2008 Aug 1;71(8):386-91.
16. Lockwood G, Griesinger G, Cometti B, et al. Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study. *Fertil Steril*. 2014;101:112–119.e113.
17. Baker VL, Jones CA, Doody K, et al. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. *Hum Reprod*. 2014;29:2212–2220.
18. Zaman AY, Coskun S, Alsanie AA, Awartani KA. Intramuscular progesterone (Gestone) versus vaginal progesterone suppository (Cyclogest) for luteal phase support in cycles of in vitro fertilization—embryo transfer: patient preference and drug efficacy. *Fertility research and practice*. 2017 Dec;3(1):1-6.
19. Doblinger J, Cometti B, Trevisan S, Griesinger G. Subcutaneous progesterone is effective and safe for luteal phase support in IVF: an individual patient data meta-analysis of the phase III trials. *PLoS One*. 2016 Mar 18;11(3):e0151388.
20. Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C, Hornstein MD. Comparison of Crinone 8% intravaginal gel

- and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. *Fertility and sterility*. 2008 Feb 1;89(2):485-7.
21. Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C, Hornstein M. Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone – impact of luteal estrogen: prospective, randomized study and post hoc analysis. *Fertil Steril*. 2011;95:617–20
  22. Chi HB, Liu NN, Li R, Tao LY, Chen LX, Qiao J. Comparison of vaginal gel and intramuscular progesterone for in vitro fertilization and embryo transfer with gonadotropin-releasing hormone antagonist protocol. *Chinese medical journal*. 2018 Jul 5;131(13):1557.
  23. Berjis K, Sarem A, Moaya M, Alaiha NM. Comparison of Intramuscular and Intravaginal Progesterone for Luteal Phase Support in IVF Cycles: a randomized clinical trial. *Journal of Family and Reproductive Health*. 2008:99-102.
  24. Nosarka S, Kruger T, Siebert I, Grové D. Luteal phase support in in vitro fertilization: meta-analysis of randomized trials. *Gynecologic and obstetric investigation*. 2005;60(2):67-74.
  25. Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. *Human Reproduction*. 2002 Sep 1;17(9):2287-99.
  26. Smits j, D., Camusm, The luteal phase and early pregnancy after combined GnRH agonist. HMG treatment for superovulation in IVF of GIFT. *Hum Reprod*. 1988 Jul ;3(s) :58590.
  27. Watters M, Noble M, Child T, Nelson S. Short versus extended progesterone supplementation for luteal phase support in fresh IVF cycles: a systematic review and meta-analysis. *Reproductive biomedicine online*. 2020 Jan 1;40(1):143-50.
  28. Griesinger G, Blockeel C, Kahler E, Pexman-Fieth C, Olofsson JI, Driessen S, Tournaye H. Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: A systematic review and individual participant data meta-analysis. *PLoS One*. 2020 Nov 4;15(11):e0241044.
  29. Salehpour S, Tamimi M, Saharkhiz N. Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal-phase support in in vitro fertilization (IVF): A randomized clinical trial. *Iranian journal of reproductive medicine*. 2013 Nov;11(11):913.c